Work

A phase 3, multicenter, open, randomized controlled clinical study of gemcitabine plus capecitabine versus gemcitabine plus carboplatin in the first-line treatment for advanced triple-negative breast cancer.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.1077

Authors: Xiaodong Liu, Weipeng Zhao, Yongsheng Jia, Yehui Shi, Xu Wang, Shufen Li, Chen Wang, Chunfang Hao, Zhongsheng Tong

Institutions: Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281641269

Cites:

Cited by:

Related to: 10